|
Characteristics
| |
ST131 subclones, number of isolates (%)
|
P
a
|
|---|
|
Total
|
H30Rx
|
H30 non-Rx
|
H41
|
H41 vs H30 non -Rx
|
H41 vs H30-Rx
|
H30 Rx vs H30 non-Rx
|
|---|
|
N = 83 (%)
|
n = 13
|
n = 40
|
n = 30
| | | |
|---|
|
PCR O type
|
|
O25b
|
55(66.3%)
|
12(92.3%)
|
40(100%)
|
3(10.0%)
|
< 0.001
|
< 0.001
| |
|
O16
|
28(33.7%)
|
1(7.7%)
|
0
|
27(90.0%)
| | | |
|
Antimicrobial resistance
|
|
ATM
|
30(36.1%)
|
12(92.3%)
|
11(27.5%)
|
7(23.3%)
| |
< 0.001
|
< 0.001
|
|
CAZ
|
22(26.5%)
|
10(76.9%)
|
5(12.5%)
|
7(23.3%)
| |
0.002
|
< 0.001
|
|
CTX
|
59(71.1%)
|
12(92.3%)
|
28(70%)
|
19(63.3%)
| | | |
|
FEP
|
26(31.3%)
|
11(84.6%)
|
10(25.0%)
|
5(16.7%)
| |
< 0.001
|
< 0.001
|
|
TZP
|
1(1.2%)
|
0
|
0
|
1(3.3%)
| | | |
|
CIP
|
58(69.9%)
|
13(100%)
|
40(100%)
|
5(16.7%)
|
< 0.001
|
< 0.001
| |
|
LEV
|
58(69.9%)
|
13(100%)
|
40(100%)
|
5(16.7%)
|
< 0.001
|
< 0.001
| |
|
AMK
|
7(8.4%)
|
3(23.1%)
|
1(2.50%)
|
3(10.0%)
| | |
0.042
|
|
SXT
|
56(67.5%)
|
10(76.9%)
|
24(60.0%)
|
22(73.3%)
| | | |
|
bla
CTX-M type
|
|
CTX-M-14
|
37(44.6%)
|
0
|
22(55.0%)
|
15(50.0%)
| |
0.001
|
< 0.001
|
|
CTX-M-15
|
22(26.5%)
|
12(92.3%)
|
7(17.5%)
|
3(10.0%)
| |
< 0.001
|
< 0.001
|
|
CTX-M-14,15
|
2(2.40%)
|
0
|
2(5.0%)
|
0
| | | |
|
CTX-M-123
|
1(1.2%)
|
0
|
0
|
1(3.3%)
| | | |
|
No ESBLb
|
21(25.3%)
|
1(7.7%)
|
11(27.5%)
|
9(30.0%)
| | | |
|
FQR genesc
|
|
5 gyrA, parC and parE mutationsd
|
51(61.4%)
|
13(100%)
|
35(87.5%)
|
3(10.0%)
|
< 0.001
|
< 0.001
| |
|
aac(6′)-Ib-cr
|
14(16.9%)
|
10(76.9%)
|
0
|
4(13.3%)
|
0.012
|
< 0.001
|
< 0.001
|
|
qnr
|
4(4.8%)
|
0
|
2(5.0%)
|
2(6.70%)
| | | |
|
Adhesins
|
|
papAH
|
22 (26.5%)
|
12(92.3%)
|
6 (15.0%)
|
4(13.3%)
| |
< 0.001
|
< 0.001
|
|
papC
|
23 (27.7%)
|
13(100%)
|
6 (15.0%)
|
4(13.3%)
| |
< 0.001
|
< 0.001
|
|
papEF
|
22 (26.5%)
|
12(92.3%)
|
7(17.5%)
|
3(10.0%)
| |
< 0.001
|
< 0.001
|
|
papG allele I
|
0
|
0
|
0
|
0
| | | |
|
papG allele II
|
21 (25.3%)
|
12(92.3%)
|
6 (15.0%)
|
3(10.0%)
| |
< 0.001
|
< 0.001
|
|
sfa/focDE
|
1 (1.2%)
|
0
|
1(2.50%)
|
0
| | | |
|
focG
|
0
|
0
|
0
|
0
| | | |
|
afa/draBC
|
7 (8.4%)
|
0
|
2(5.0%)
|
5(16.7%)
| | | |
|
fimH
|
82 (98.8%)
|
13(100%)
|
39(97.5%)
|
30(100%)
| | | |
|
gafD
|
0
|
0
|
0
|
0
| | | |
|
sfaS
|
7 (8.4%)
|
3(23.1%)
|
3(7.5%)
|
1(3.3%)
| | | |
|
Toxins
|
|
hlyA
|
14 (16.9%)
|
11(84.6%)
|
1(2.50%)
|
2(6.70%)
| |
< 0.001
|
< 0.001
|
|
cnf1
|
10 (12.0%)
|
8(61.5%)
|
1(2.50%)
|
1(3.3%)
| |
0.002
|
< 0.001
|
|
cdtB
|
0
|
0
|
0
|
0
| | | |
|
cvaC
|
3 (3.6%)
|
0
|
0
|
3(10.0%)
|
0.042
| | |
|
Siderophores
|
|
fyuA
|
81 (97.6%)
|
13(100%)
|
38(95.0%)
|
30(100%)
| | | |
|
iutA
|
77 (92.8%)
|
13(100%)
|
38(95.0%)
|
26(86.7%)
| | | |
|
Capsules
|
|
kpsMT II
|
62 (74.7%)
|
9(69.2%)
|
33(82.5%)
|
20(66.7%)
| | | |
|
kpsMT III
|
0
|
0
|
0
|
0
| | | |
|
kpsMT K1
|
10 (12.0%)
|
2(15.4%)
|
5(12.5%)
|
3(10.0%)
| | | |
|
kpsMT K5
|
47 (56.6%)
|
11(84.6%)
|
29(72.5%)
|
7(23.3%)
|
< 0.001
|
0.001
| |
|
Miscellaneous
|
|
nfaE
|
0
|
0
|
0
|
0
| | | |
|
rfc
|
0
|
0
|
0
|
0
| | | |
|
malX
|
76 (91.6%)
|
13(100%)
|
37(92.5%)
|
26(86.7%)
| | | |
|
traT
|
73 (88.0%)
|
13(100%)
|
32(80.0%.)
|
28(93.3%)
| | | |
|
Virulence scorese
|
7
|
9
|
7
|
6
| |
0.001
|
0.001
|
-
a
P values, by either χ2 or Fisher’s exact test or Mann-Whitney test, are shown where P < 0.05
-
bESBL, CTX-M-type extended-spectrum-β-lactamase genes
-
cFQR, fluoroquinolone resistance
-
dGyrA S83 L, D87N, ParC S80I, E84V, and ParE I529L
-
emedian number of virulence factors (range)
